758-P: Treatment with Testosterone Undecanoate Injections (TU) Improves Estimated Glomerular Filtration Rate (eGFR) in Men with Hypogonadism and Type 2 Diabetes Mellitus: Update of Real-World Data

Abstract

Background: Reduced eGFR is associated with increased risk of cardiovascular disease and mortality. Methods: In a registry of 865 men with hypogonadism, 361 men (41.7%) had T2DM. 183 received TU 1000 mg every 12 weeks (T-group). 178 opted against treatment (CTRL). Changes over time between groups were compared and adjusted for age, weight, waist circumference, fasting glucose, blood pressure, lipids and quality of life to account for baseline differences between the groups. eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) formula. Results: Mean follow-up 8.7±3.1, baseline age: 61.8±5.3 years. Creatinine decreased by 0.16±0.03 mg/dL (unadjusted from 0.95±0.16 to 0.83±0.09) at 12 years in the T-group and increased by 0.33±0.03 mg/dL (1.00±0.14 to 1.26±0.42) in CTRL (p<0.0001 for both). T-group: eGFR increased by 15.1±5.6 mL/min/1.73 m² (82.8±12.8 to 92.3±10.0). The peak mean value was recorded in year 9 after which a small but steady decline occurred. CTRL: eGFR decreased progressively by 22.9±5.6 mL/min/1.73 m² (77.35±13.9 to 64.4±32.5) (p<0.0001 for both). Systolic blood pressure decreased in the T-group by 33.1±1.2 mmHg (163.05±13.5 to 130.23±6.5) and increased in CTRL by 18.3±1.2 mmHg (145.6±14.6 to 158.3±15.1) (p<0.0001 for both). Diastolic blood pressure decreased in the T-group by 20.3±0.9 mmHg (97.4±10.9 to 75.4±3.3) and increased in CTRL by 12.5±0.9 mmHg (84.8±10.3 to 94.3±8.9) (p<0.0001 for both). During the entire observation period, 15 deaths (8.3%) and no cardiovascular events occurred in the T-group. In CTRL, 61 deaths (34.3%), 56 cases of myocardial infarction (31.5%) and 56 cases of stroke (31.5%) were recorded (p<0.0001 for all). Nephropathy occurred in 0.01% in the T-group and in 2.8% in CTRL (p<0.05). Conclusions: Long-term testosterone therapy in men with hypogonadism and T2DM prevents age-related deterioration in GFR. Disclosure K. S. Haider: Other Relationship; Self; Bayer AG. A. Haider: Other Relationship; Self; Bayer AG. F. Saad: Consultant; Self; Bayer AG, Stock/Shareholder; Self; AbbVie Inc., Bayer AG, Novo Nordisk. Funding Bayer AG